Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Vorinostat | Suberoylanilide Hydroxamic Acid, N-Hyrdroxy-N'-phenyloctanediamide. CAS No. 149647-78-9. Product ID: 8-04769. Molecular formula: C14H20N2O3. Mole weight: 264.32. Purity: 0.985. |  |
| Vorinostat | Vorinostat (rINN) also known as suberanilohydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.Vorinostat is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after treatment with other medicines. The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks. Uses: Designed for use in research and industrial production. Additional or Alternative Names: Suberoylanilidehydroxamic Acid;N-Hydroxy-N-phenyloctanediamide;Vorinostat/SAHA;Suberoylanilide Hydroxamic Acid. Product Category: Inhibitors. Appearance: White crystalline solid. CAS No. 149647-78-9. Molecular formula: C14H20N2O3. Mole weight: 264.32. Purity: 0.9962. Density: 1.174 g/cm³. Product ID: ACM149647789. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Vorinostat | Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1 , HDAC2 and HDAC3 (Class I) , HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV) , with ID 50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis [1] [4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification [7]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SAHA; Suberoylanilide hydroxamic acid. CAS No. 149647-78-9. Pack Sizes: 10 mM * 1 mL; 250 mg; 500 mg; 1 g; 5 g. Product ID: HY-10221. |  |
| Vorinostat | Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM. Uses: Antineoplastic agents; histone deacetylase inhibitors. Synonyms: MK-0683, MK 0683, MK0683, SAHA, M344, CCRIS 8456, HSDB 7930, Vorinostat, suberoylanilide hydroxamic acid, Zolinza. Grades: >98%. CAS No. 149647-78-9. Molecular formula: C14H20N2O3. Mole weight: 264.3. |  |
| Vorinostat Amide Impurity | One of the impurities of Vorinostat, which is a HDAC inhibitor and has been found to exhibit anti-angiogenic activity and could induce differentiation in breast cancer cells. Molecular formula: C14H20N2O2. Mole weight: 248.33. | |
| Vorinostat Amination Derivative | One of the impurities of Vorinostat, which is a HDAC inhibitor and has been found to exhibit anti-angiogenic activity and could induce differentiation in breast cancer cells. Synonyms: p-Aminomethyl Vorinostat; N1-[4-(Aminomethyl)phenyl]-N8-hydroxy-octanediamide. CAS No. 1160823-16-4. Molecular formula: C15H23N3O3. Mole weight: 293.37. | |
| Vorinostat Dimer Impurity | One of the impurities of Vorinostat, which is a HDAC inhibitor and has been found to exhibit anti-angiogenic activity and could induce differentiation in breast cancer cells. Molecular formula: C28H38N4O6. Mole weight: 526.64. | |
| Vorinostat Impurity | One of the impurities of Vorinostat, which is a HDAC inhibitor and has been found to exhibit anti-angiogenic activity and could induce differentiation in breast cancer cells. Synonyms: N-Hydroxy-N,N-di-(N'-Phenyl-Octanediamide)amine. Molecular formula: C28H37N3O5. Mole weight: 495.62. | |
| Vorinostat Impurity 1 | One of the impurities of Vorinostat, which is a HDAC inhibitor and has been found to exhibit anti-angiogenic activity and could induce differentiation in breast cancer cells. CAS No. 866824-87-5. Molecular formula: C28H37N3O5. Mole weight: 495.62. | |
| Vorinostat Impurity 2 | One of the impurities of Vorinostat, which is a HDAC inhibitor and has been found to exhibit anti-angiogenic activity and could induce differentiation in breast cancer cells. Molecular formula: C20H24N2O2. Mole weight: 324.43. | |
| Suberoylanilide-d5 Hydroxamic Acid (SAHA-d5, N-Hydroxy-N-phenyl-d5-octanediamide, Zolinza-d5, Vorinostat-d5) | A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells. Group: Biochemicals. Alternative Names: SAHA-d5; N-Hydroxy-N-phenyl-d5-octanediamide;Zolinza-d5. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. |  Worldwide |
| Suberoylanilide Hydroxamic Acid (SAHA, Zolinza, Vorinostat) | A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells. Group: Biochemicals. Alternative Names: SAHA; N-Hydroxy-N-phenyloctanediamide; N-Hydroxy-N-phenyloctanediamide; Zolinza; Suberoylanilide-hydroxamic acid, Vorinostat. Grades: Highly Purified. CAS No. 149647-78-9. Pack Sizes: 100mg. US Biological Life Sciences. | Worldwide |
| AR-42 | AR-42 is an orally available, broad-spectrum deactylation inhibitor of both histone and non-histone proteins which play an important role in the regulation of gene expression, cell growth and survival. In preclinical studies, AR-42 has demonstrated greater potency and activity in solid and liquid tumors when compared to vorinostat and other deacetylase inhibitors. AR-42 is currently being studied in an investigator-initiated Phase I/IIa clinical study in adult patients with relapsed or refractory multiple myeloma, chronic lymphocytic leukemia or lymphoma. Synonyms: HDAC-42; HDAC42; HDAC 42; OSU-HDAC-42; OSU HDAC 42; AR-42; AR42; AR 42. Grades: 98%. CAS No. 935881-37-1. Molecular formula: C18H20N2O3. Mole weight: 312.37. | |
| BPR1J-340 | BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy. Synonyms: BPR1J 340; BPR1J340. Grades: 98%. CAS No. 1395051-72-5. Molecular formula: C29H34N8O3. Mole weight: 542.63. | |
| CG200745 | CG200745 is a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI). Like other inhibitors, CG200745 has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. CG200745 inhibited deacetylation of histone H3 and tubulin as much as vorinostat and belinostat did. CG200745 also inhibited growth of prostate cancer cells, increased sub-G1 population, and activated caspase-9, -3 and -8 in LNCaP, DU145 and PC3 cells. These results indicate that CG200745 induces apoptosis. The preclinical results show that combination treatment with docetaxel and new HDACI, CG200745, potentiated anti-tumor effect in hormone-refractory prostate cancer (HRPC) cells via activation of apoptosis. Synonyms: Ivaltinostat; CG-200745; CG-2; (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide. CAS No. 936221-33-9. Molecular formula: C24H33N3O4. Mole weight: 427.55. | |
| EDO-S101 | EDO-S101 is a pan HDAC inhibitor (IC50 = 9, 9 and 25 nM for HDAC1, HDAC2 and HDAC3, respectively). EDO-S101 is a first-in-class fusion molecule that combines DNA damaging effect of bendamustine with the pan-HDACi vorinostat. Synonyms: 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; EDO-S101; EDO-S 101; EDO-S-101; EDO-S101 HCl; EDO-S101 hydrochloride; Tinostamustine hydrochloride. CAS No. 1236199-60-2. Molecular formula: C19H28Cl2N4O2. Mole weight: 415.36. | |
Our database is helping our users find suppliers everyday.
